Strs Ohio increased its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,717 shares of the biopharmaceutical company’s stock after purchasing an additional 893 shares during the quarter. Strs Ohio’s holdings in Regeneron Pharmaceuticals were worth $18,772,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of REGN. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $292,457,000. FMR LLC boosted its position in Regeneron Pharmaceuticals by 6.6% during the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after acquiring an additional 330,875 shares during the period. Morgan Stanley boosted its position in Regeneron Pharmaceuticals by 70.6% during the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after acquiring an additional 192,236 shares during the period. American Century Companies Inc. boosted its position in Regeneron Pharmaceuticals by 16.6% during the 4th quarter. American Century Companies Inc. now owns 1,003,471 shares of the biopharmaceutical company’s stock worth $374,796,000 after acquiring an additional 142,779 shares during the period. Finally, Hexavest Inc. acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $37,955,000. 66.97% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on REGN. Guggenheim downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $466.00 to $425.00 in a research note on Friday, February 22nd. TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective on the stock in a research note on Thursday, February 7th. BidaskClub downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 7th. Finally, Cowen reissued a “hold” rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average target price of $413.94.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $5.10 by $1.74. The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.73 billion. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The company’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.23 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 12.42% of the company’s stock.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.